論文

査読有り
2020年2月8日

Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival

Neuro-Oncology
  • Paul W Sperduto
  • ,
  • Shane Mesko
  • ,
  • Jing Li
  • ,
  • Daniel Cagney
  • ,
  • Ayal Aizer
  • ,
  • Nancy U Lin
  • ,
  • Eric Nesbit
  • ,
  • Tim J Kruser
  • ,
  • Jason Chan
  • ,
  • Steve Braunstein
  • ,
  • Jessica Lee
  • ,
  • John P Kirkpatrick
  • ,
  • Will Breen
  • ,
  • Paul D Brown
  • ,
  • Diana Shi
  • ,
  • Helen A Shih
  • ,
  • Hany Soliman
  • ,
  • Arjun Sahgal
  • ,
  • Ryan Shanley
  • ,
  • William Sperduto
  • ,
  • Emil Lou
  • ,
  • Ashlyn Everett
  • ,
  • Drexell Hunter Boggs
  • ,
  • Laura Masucci
  • ,
  • David Roberge
  • ,
  • Jill Remick
  • ,
  • Kristin Plichta
  • ,
  • John M Buatti
  • ,
  • Supriya Jain
  • ,
  • Laurie E Gaspar
  • ,
  • Cheng-Chia Wu
  • ,
  • Tony J C Wang
  • ,
  • John Bryant
  • ,
  • Michael Chuong
  • ,
  • James Yu
  • ,
  • Veronica Chiang
  • ,
  • Toshimichi Nakano
  • ,
  • Hidefumi Aoyama
  • ,
  • Minesh P Mehta

記述言語
掲載種別
研究論文(学術雑誌)
DOI
10.1093/neuonc/noaa025
出版者・発行元
Oxford University Press (OUP)

<title>Abstract</title>
<sec>
<title>Background</title>
Breast cancer treatment is based on estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2). At the time of metastasis, receptor status can be discordant from that at initial diagnosis. The purpose of this study was to determine the incidence of discordance and its effect on survival and subsequent treatment in patients with breast cancer brain metastases (BCBM).


</sec>
<sec>
<title>Methods</title>
A retrospective database of 316 patients who underwent craniotomy for BCBM between 2006 and 2017 was created. Discordance was considered present if the ER, PR, or HER2 status differed between the primary tumor and the BCBM.


</sec>
<sec>
<title>Results</title>
The overall receptor discordance rate was 132/316 (42%), and the subtype discordance rate was 100/316 (32%). Hormone receptors (HR, either ER or PR) were gained in 40/160 (25%) patients with HR-negative primary tumors. HER2 was gained in 22/173 (13%) patients with HER2-negative primary tumors. Subsequent treatment was not adjusted for most patients who gained receptors—nonetheless, median survival (MS) improved but did not reach statistical significance (HR, 17–28 mo, P = 0.12; HER2, 15–19 mo, P = 0.39). MS for patients who lost receptors was worse (HR, 27–18 mo, P = 0.02; HER2, 30–18 mo, P = 0.08).


</sec>
<sec>
<title>Conclusions</title>
Receptor discordance between primary tumor and BCBM is common, adversely affects survival if receptors are lost, and represents a missed opportunity for use of effective treatments if receptors are gained. Receptor analysis of BCBM is indicated when clinically appropriate. Treatment should be adjusted accordingly.


</sec>
<sec>
<title>Key Points</title>
1. Receptor discordance alters subtype in 32% of BCBM patients.


2. The frequency of receptor gain for HR and HER2 was 25% and 13%, respectively.


3. If receptors are lost, survival suffers. If receptors are gained, consider targeted treatment.


</sec>

リンク情報
DOI
https://doi.org/10.1093/neuonc/noaa025
URL
http://academic.oup.com/neuro-oncology/advance-article-pdf/doi/10.1093/neuonc/noaa025/32924880/noaa025.pdf

エクスポート
BibTeX RIS